Compare TOVX & PMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOVX | PMI |
|---|---|---|
| Founded | 2001 | 1981 |
| Country | United States | United States |
| Employees | N/A | 75 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7M | 14.1M |
| IPO Year | 2012 | N/A |
| Metric | TOVX | PMI |
|---|---|---|
| Price | $0.23 | $0.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | 1.6M | ★ 3.5M |
| Earning Date | 05-13-2026 | 06-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.11 |
| 52 Week High | $0.86 | $13.68 |
| Indicator | TOVX | PMI |
|---|---|---|
| Relative Strength Index (RSI) | 39.75 | 37.46 |
| Support Level | $0.23 | $0.11 |
| Resistance Level | $0.27 | $0.20 |
| Average True Range (ATR) | 0.02 | 0.02 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 15.32 | 3.78 |
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.